Four Swiss-based companies will received state funding to develop a range of new drugs to treat coronavirus, which are expected to be available by the end of 2022.
This content was published on
1 minute
swissinfo.ch/dos
Português
pt
Governo suíço financia quatro novos medicamentos contra a Covid
The contracts were signed in the context of the Federal Funding Programme for Covid-19 Medicines, run by the Federal Office for Public Health (FOPH) and the Swiss Innovation Agency Innosuisse, the government said on MondayExternal link.
The total value of the four deals is CHF27 million ($29.2 million).
The projects aim to treat a range of the symptoms caused by a Covid-19 infection and to mitigate the length and severity of illness.
Two of the drugs are monoclonal antibody treatments: one for the neuropsychiatric symptoms in sufferers of long Covid, and the other for use on patients at risk of a severe course of Covid-19. A third project is developing an oral pulmonary vasodilator which makers hope will prevent respiratory failure and reduce the need for artificial ventilation.
A final project is an antiviral and anti-inflammatory to treat “all severities of Covid-19”.
Switzerland will enjoy “certain benefits” in return for its investment, the government stated. This includes having a first option on purchases of the drugs.
The government’s medical procurement capabilities to tackle the coronavirus pandemic come under the remit of the Covid-19 law, approved for a second time by voters in a nationwide referendum two weeks ago.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
Swiss price watchdog slams excessive prices for generic medicines
This content was published on
The cheapest generic medicines available in Switzerland are more than twice as expensive as in other countries, according to a study by the Swiss price watchdog.
Nature should not figure in net zero calculations: academic study
This content was published on
The natural removal of CO2 from the atmosphere by forests or oceans should not be included in the net-zero balance of climate protection measures, argue researchers.
This content was published on
None of the 15 major Swiss retail banks is meeting international climate and biodiversity targets, according to a ranking by WWF Switzerland.
This content was published on
Nestlé's new CEO Laurent Freixe, has presented plans for the future of the world's largest food company, after his first few weeks in office.
Swiss foreign minister calls on Moscow to end Ukraine war
This content was published on
It's high time Moscow ended its war against Ukraine, Swiss foreign minister Ignazio Cassis tells the UN Security Council.
This content was published on
The only alternative to the UN Palestinian agency’s work in Gaza is to allow Israel to run services there, Philippe Lazzarini, UNRWA Commissioner-General, told reporters in Geneva on Monday.
Study reveals food culture differences between Switzerland and neighbours
This content was published on
Three-quarters of Swiss people consider eating to be a pleasurable, social activity, a new survey reveals. Healthy eating, however, plays a much less important role, it found.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
It’s not all about age: why Covid hits some people harder than others
This content was published on
New insights: two studies involving Swiss scientists suggest genes and blood sugar levels play a crucial role in the course of Covid-19.
This content was published on
Should we be afraid of virus variants? Will vaccines be effective against new virus forms? Genomic epidemiologist Emma Hodcroft offers some insight.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.